Trial start date April 29, 2020. Estimated completion date May 2, 2023 -- Offical Title: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS
Phase 1/2/3 run concurrently and will be done in 2023.(In Healthy Individuals) There's usually a Phase 4. Do you feel like a guinea pig? You should. Unless you're a PureBlood.
A six-month study using this trial was published. Interestingly, During the blinded, placebo-controlled period, 15 participants in the BNT162b2 group and 14 in the placebo group died; during the open-label period, 3 participants in the BNT162b2 group and 2 in the original placebo group who received BNT162b2 after unblinding died. None of these deaths were considered to be related to BNT162b2 by the investigators. Causes of death were balanced between BNT162b2 and placebo groups (Table S4).
So while preventative Efficacy was sustained, fatalities were equal across both groups.